The limitations of this study are a lack of (1) testing RCF + Ixz in mouse models of CRPC/NEPC and (2) identifying specific information on how elevated XBP1s and reduced PERK can increase RCF + Ixz cell death in advanced CRPC/NEPC, but with fewer effects on non-cancer cells. Here, EIF2AK3 is linked to cancer.